Safety is at the core of ATC. However, safety is interrelated with efficiency. Air and Ground Safety Nets have been developed to increase the achieved level of safety. Necessarily, Ground and Air Safety Nets have to evolve to keep up with the challenges originating from ever increasing traffic density and complexity. ATM evolutions necessary to safely handle increasing traffic demand or to improve efficiency of air transportation impose new challenging requirements on existing Safety Nets. Future Air and Ground safety nets need to support Trajectory Based Operations and new separation modes: they must provide necessary alerts for actual or potential hazardous situations in an efficient way and avoid or minimise unnecessary alerts. The SESAR 2020 PJ11-CAPITO project will anticipate these required evolutions to maintain, and if possible improve the level of safety. It will also support the safe integration of new airspace users such as Remotely Piloted Aircraft Systems (RPAS) in ATM. PJ11-CAPITO work is focussed on developing and validating requirements in five solutions: one addressing the ground safety nets (in particular Short Term Conflict Alert) and four focussing on the development of specific variants of the new generation of Airborne Collision Avoidance Systems: ACAS Xa for commercial aviation, ACAS Xu for RPAS, ACAS Xo for Specific operations such as parallel approaches, and ACAS Xp for General Aviation. Airborne Collision Avoidance Systems need to be interoperable worldwide, which is primarily ensured through the standardisation process. PJ11 CAPITO will federate European requirements’ capture and ensure that they are taken into account in the global standardisation processes. PJ11 CAPITO unites key European aviation partners including Air Navigation Service Providers, Ground Industry, Airborne industry and EUROCONTROL so that required complementary expertise is available to achieve these ambitious objectives.

The GENIALG project aims to boost the Blue Biotechnology Economy (BBE) by increasing the production and sustainable exploitation of two high-yielding species of the EU seaweed biomass: the brown alga Saccharina latissima and the green algae Ulva spp. GENIALG will demonstrate the economic feasibility and environmental sustainability of cultivating and refining seaweed biomass in multiple use demanded products of marine renewable origin. The consortium integrates available knowledge in algal biotechnology and ready to use reliable eco-friendly tools and methods for selecting and producing high yielding strains in economically feasible quantities and qualities. By cracking the biomass and supplying a wide diversity of chemical compounds for existing as well as new applications and markets, GENIALG will anticipate the economic, social and environmental impacts of such developments in term of economic benefit and job opportunities liable to increase the socio-economic value of the blue biotechnology sector. In a larger frame, conservation and biosafety issues will be addressed as well as more social aspects such as acceptability and competition for space and water regarding other maritime activities. To achieve these objectives GENIALG will foster a trans-sectorial and complementary consortium of scientists and private companies. • GENIALG will involve a diversity of private companies already positioned in the seaweed sector individually for different applications (texturants, feed, agriculture, bioplastics, pharmaceuticals, personal care products…) in order to strengthen interactions for developing a bio-refinery concept and accelerate efficient and sustainable exploitation of seaweed biomass to bring new high-value products on the market.

With CO2 emission at 36% and energy consumption at 40%, building sector is far from sustainability. The need for construction materials to achieve climate neutral buildings reaches 0.2 m3 per m2 of net floor in France, leading to several billions of m3 in Europe by 2050. EASI ZERo proposes a global system to cut the environmental impact by rising the thermal performance of buildings envelope by 20% with bio-sourced and recycled materials. This include grown mycelium, wood fibres, low carbon foam, recycled raw material for spayed renders, multifunctional building bricks, and healthy finishes. This unique portfolio of tailored components results from manufacturing and sourcing with reduced CO2 emission and embodied energy. It will demonstrate cost-efficient and easy installation in green deep renovation and also new construction operations. The re-use of components and the integration of recycled materials enhance circular economy by closing carbon cycle and raise resilience in the construction value chain. Design tools, numerical database and material passport will optimise the materials combination towards maximum sustainability and minimum payback time for any typology of buildings and conditions (climate, aesthetics, specific risk). Projects use-cases will show real buildings reaching durable high environmental performance and carbon emission over more than 40 years and neutral energy balance with integrated PV generation where relevant. A multidisciplinary consortium will support these objectives and benefit from project outcomes, as universities, technology developers, construction material producers and building engineers. Use-cases will especially consider social housing. Outcomes will positively impact i) European competitiveness with manufacturing of sustainable and clean construction materials and easy installation on any building in EU stock ii) raise resilience thanks to circular economy, eco-design and digitization of the EASI ZERo renovation system.

The main objective of the MUPIA project is to demonstrate a cost-efficient manufacturing process for a high end MEMS gyroscope for aerospace Applications. Both the sensor element and the packaging process is critical to achieve a precise, long term stable and reliable component. The consortium consist of SINTEF and Cerinnov, which together with sub Suppliers cover both the necessary silicon MEMS processing and the high end ceramic packaging technology needed to reach the goal of the project. SINTEF has worked with industrialisation of MEMS components since the 1960s. Despite being a research industry, SINTEF holds the certifications ISO 9001:2015, ISO 14001:2015 and OHSAS 18001:2007 and have a regular production of MEMS components for the petroleum, medical and aerospace industry. Cerinnov has expertise in laser processes for ablation and sintering. They will collaborate with a sub Suppliers with the development of the package for the gyroscope.

REFINE proposes a Regulatory Science Framework for the risk-benefit assessment of medical products and medical devices that are based on nanomedicines and biomaterials. The heart of our framework is the development of a product-specific Decision Support System that identifies the most efficient way to deliver the data required by regulation by the best-fitting methods. The decision tree will explicate the product’s specific regulatory challenges and the priorities of both missing data and missing methods to match these challenges. It will thus allow planning a cost-and time efficient strategy both for necessary measurements and for the advancement of methods. Our approach is aligned with the industrial R&D practice of stage gating. We will demonstrate the relevance of the framework for the most pressing regulatory challenges, which are: borderline products, nanosimilars, and products combining several functionalities. In order to do so, we will identify the regulatory challenges with Regulation Authorities from Europe and abroad, and design methods for tiered decision tree, guided by the latest scientific knowledge. We will study/predict physiological distribution of nanomedicines and biomaterials, as well as develop and validate new analytical or experimental methods and assays requested by the regulators. These latter development will be performed in a quality management system, ensuring the possible standardisation of our assays. REFINE will gather a wide community of stakeholders in regulation, industry, science, technology development, patients, and end-users, into a Consortium for the Advancement of Regulatory Science in Biomaterials and Nanomedicine.